Autosomal dominant polycystic kidney disease currently has only one treatment approved by the U.S. Food and Drug Administration

Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.